Adrenomedullin Expression in Alzheimer's Brain

Author(s): Ana Patricia Fernandez, Julia Serrano Masa, María Atocha Guedan, Hunter S. Futch, Ricardo Martínez-Murillo.

Journal Name: Current Alzheimer Research

Volume 13 , Issue 4 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Adrenomedullin (AM) is a potent vasodilator peptide highly expressed throughout the brain and originally isolated from pheochromocytoma cells. In addition to its vasoactive properties, AM is considered a neuromodulator that possesses antiapoptotic and antioxidant properties that suggest that this peptide can protect the brain from damage. In a previous study, we found that AM exerts a neuroprotective action in the brain and that this effect may be mediated by regulation of nitric oxide synthases, matrix metalloproteases, and inflammatory mediators. AM upregulation contributes to neuroprotection, but understanding the precise roles played by AM and its receptor (RAMP2) in neurodegenerative diseases including Alzheimer´s disease (AD), awaits further research. In search of Alzheimer´s biomarkers, the expression levels of peptides with endothelial vasodilatory action, including AM, were found to be significantly altered in mild AD or during pre-dementia stage of mild cognitive impairment. These studies concluded that ratio of AM or its precursor fragment mid-regional proAM in blood hold promise as diagnostic marker for AD. We are now presenting a study regarding the hypothesis that the AMRAMP2 system might be implicated in the pathophysiology of AD.

Keywords: Adrenomedullin, Alzheimer, human, neuroprotection, transgenic mice.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 13
ISSUE: 4
Year: 2016
Page: [428 - 438]
Pages: 11
DOI: 10.2174/1567205013666160229112725
Price: $58

Article Metrics

PDF: 34
HTML: 3
EPUB: 1
PRC: 1